Skip to content
10-Q

Quarterly Report

9 Meters Biopharma, Inc.

0001551986-23-000038

← back to feed
Filed
May 15, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 12, 2023 14.46M sh
Shares Diluted Q1 2023 · Mar 31, 2023 13.59M sh
Shares Diluted restated Q1 2023 · Mar 31, 2022 12.91M sh
Capex Q1 2023 · Mar 31, 2023 $0
Capex Q1 2023 · Mar 31, 2022 $2.84K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$9.75M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$9.75M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $6.94M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $12.65M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $37.24M
Stockholders Equity Q1 2023 · Mar 31, 2023 −$6.3M
Stockholders Equity Q1 2023 · Dec 31, 2022 $2.4M
Stockholders Equity Q1 2023 · Mar 31, 2022 $30.94M
Stockholders Equity Q1 2023 · Dec 31, 2021 $41.6M
Current Liabilities Q1 2023 · Mar 31, 2023 $15.58M
Current Liabilities Q1 2023 · Dec 31, 2022 $30.7M
Total Liabilities Q1 2023 · Mar 31, 2023 $15.61M
Total Liabilities Q1 2023 · Dec 31, 2022 $30.75M
Current Assets Q1 2023 · Mar 31, 2023 $9.2M
Current Assets Q1 2023 · Dec 31, 2022 $33.02M
Total Assets Q1 2023 · Mar 31, 2023 $9.31M
Total Assets Q1 2023 · Dec 31, 2022 $33.15M
Eps Diluted Q1 2023 · Mar 31, 2023 −$1.02
Eps Diluted restated Q1 2023 · Mar 31, 2022 −$0.88
Eps Basic Q1 2023 · Mar 31, 2023 −$1.02
Eps Basic restated Q1 2023 · Mar 31, 2022 −$0.88
Sga Expense Q1 2023 · Mar 31, 2023 $2.99M
Sga Expense Q1 2023 · Mar 31, 2022 $3M
Net Income Q1 2023 · Mar 31, 2023 −$13.87M
Net Income Q1 2023 · Mar 31, 2022 −$11.35M
Operating Income Q1 2023 · Mar 31, 2023 −$12.79M
Operating Income Q1 2023 · Mar 31, 2022 −$11.36M